Cite
HARVARD Citation
Ksienski, D. et al. (2022). Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab. Journal of geriatric oncology. 13 (2), pp. 220-227. [Online].